Protara Therapeutics
TARA
35 hedge funds and large institutions have $19.1M invested in Protara Therapeutics in 2024 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 14 increasing their positions, 7 reducing their positions, and 7 closing their positions.
433% more call options, than puts
Call options by funds: $16K | Put options by funds: $3K
100% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 7
0.11% less ownership
Funds ownership: 50.75% → 50.64% (-0.11%)
8% less funds holding
Funds holding: 38 → 35 (-3)
14% less capital invested
Capital invested by funds: $22.2M → $19.1M (-$3.12M)
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$1.54M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$682K |
| 3 |
Renaissance Technologies
New York
|
+$383K |
| 4 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
+$193K |
| 5 |
Two Sigma Advisers
New York
|
+$146K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.28M |
| 2 |
AC
Armistice Capital
New York
|
-$1.08M |
| 3 |
PFMU
Privium Fund Management (UK)
London,
United Kingdom
|
-$233K |
| 4 |
SC
Stempoint Capital
New York
|
-$84.7K |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$51.4K |
TARA Hedge Fund Activity: Q3 2024 in Review
35 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q3 2024, worth a combined $19.1M — down 14% from $22.2M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of TARA and 5 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 14 added.
The largest buyer was Woodline Partners, adding an estimated $1.54M. The largest seller was Opaleye Management, cutting an estimated $1.28M.
- 35 institutional investors held Protara Therapeutics (TARA) as of Q3 2024, down from 38 in Q2 2024.
- Funds reported $19.1M of Protara Therapeutics stock for Q3 2024, down 14% quarter-over-quarter.
- 5 funds opened new Protara Therapeutics positions in Q3 2024 and 7 closed out, a net change of -2 holders.
- The largest Protara Therapeutics buyer in Q3 2024 was Woodline Partners, an estimated $1.54M added.
- The largest Protara Therapeutics seller in Q3 2024 was Opaleye Management, an estimated $1.28M sold.
Based on aggregated 13F filings for Q3 2024.